Arrowstreet Capital
KPTI icon

Arrowstreet Capital’s Karyopharm Therapeutics KPTI Stock Holding History

Arrowstreet Capital’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,984
Closed -$202K – 1376
2022
Q2 		$202K Buy
+2,984
New +$274K ﹤0.01% 1164
2016
Q4 		– Sell
-1,379
Closed -$201K – 2124
2016
Q3 		$201K Buy
+1,379
New +$166K ﹤0.01% 1424

Other funds holding KPTI

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return

Arrowstreet Capital's KPTI Position: Q3 2022 in Review

Arrowstreet Capital sold out of Karyopharm Therapeutics (KPTI) in Q3 2022, closing a stake of 2,984 shares — an estimated $202K sold.

Arrowstreet Capital first reported a position in KPTI in Q3 2016 and held it in 2 quarters. The position peaked at $202K in Q2 2022. 147 funds tracked by Wall St. Rank hold KPTI as of Q3 2022.

  • Arrowstreet Capital reported no remaining Karyopharm Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Arrowstreet Capital sold 2,984 Karyopharm Therapeutics shares in Q3 2022, an estimated $202K.
  • Arrowstreet Capital first reported a position in Karyopharm Therapeutics in Q3 2016 and held it in 2 quarters.
  • Arrowstreet Capital's Karyopharm Therapeutics position peaked at $202K in Q2 2022.
  • 147 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2022.

Based on Arrowstreet Capital's 13F filing for Q3 2022, filed 14 Nov 2022.